Study: Is Rosacea Hereditary?
March 04, 2022

A study in the Journal of Clinical and Aesthetic Dermatology dove into the hereditary predisposition of rosacea within families.

New Drugs and Therapies in 2022: Acne, Rosacea, and Pruritus
January 24, 2022

Patients suffering from several dermatologic diseases and conditions including acne, rosacea, and pruritus can largely benefit from the new and exciting therapies and treatment modalities that have recently become available.

Expert Pearls for Treating Rosacea Patients
January 18, 2022

Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.

Multimodal Plan Combats Combination Rosacea
December 23, 2021

Hilary Baldwin, MD, used examples of challenging cases to show how to develop successful combination regimens.

New Approaches in Rosacea Therapy
November 14, 2021

Neal Bhatia, MD, highlights new approaches in rosacea therapy in his session at the Fall Clinical Dermatology Conference for PAs & NPs.

Rosacea Update: Facial Erythema’s Importance
October 05, 2021

Optimizing rosacea treatment outcomes isn’t only about papules and pustules. Facial erythema needs to be part of an effective management plan.

Using Combination Therapies and Avoiding Subtypes for Rosacea
October 01, 2021

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Recognizing and Treating Rosacea in Skin of Color
September 22, 2021

Hilary Baldwin, MD, presented on how to recognize, diagnose, and treat rosacea in patients with skin of color at the Skin of Color Update 2021.

New NRS Recommendations for Rosacea
September 17, 2021

The National Rosacea Society has recently released recommendations based on a group discussion regarding updates in rosacea.

Full Pipeline, Customized Diagnoses Expand Options for Rosacea
September 08, 2021

Challenges with overlaps in diagnosis and classification based on rosacea’s 4 subtypes are creating a new focus on features of the condition in each patient. A pipeline of new drugs awaiting FDA approvals could further expand options.